Loading...
XNAS
AUTL
Market cap668mUSD
Jul 28, Last price  
2.51USD
1D
-0.40%
1Q
91.60%
IPO
-90.42%
Name

Autolus Therapeutics PLC

Chart & Performance

D1W1MN
P/E
—
P/S
66.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
42.74%
Rev. gr., 5y
28.33%
Revenues
10m
+496.00%
94,1121,212,0001,693,0001,045,3432,908,000242,0002,330,0006,194,0001,698,00010,120,000
Net income
-221m
L+5.89%
-7,464,150-12,550,000-19,727,000-31,114,488-123,849,000-142,094,000-142,096,000-148,839,000-208,383,000-220,662,000
CFO
-206m
L+41.68%
-3,325,456-9,849,000-16,360,000-25,847,353-101,484,000-117,758,000-117,861,000-112,308,000-145,587,000-206,271,000

Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
URL
https://www.autolus.com/
IPO date
Jun 22, 2018
Employees
399
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑092017‑092016‑092015‑09
Income
Revenues
10,120
496.00%
1,698
-72.59%
6,194
165.84%
Cost of revenue
149,823
203,291
311,111
Unusual Expense (Income)
NOPBT
(139,703)
(201,593)
(304,917)
NOPBT Margin
Operating Taxes
1,528
(19)
(24,366)
Tax Rate
NOPAT
(141,231)
(201,574)
(280,551)
Net income
(220,662)
5.89%
(208,383)
40.01%
(148,839)
4.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
549,977
(883)
153,610
BB yield
-91.72%
0.08%
-85.11%
Debt
Debt current
2,998
10,106
5,038
Long-term debt
102,260
100,881
43,474
Deferred revenue
Other long-term liabilities
245,026
171,256
126,016
Net debt
(482,765)
(128,579)
(333,924)
Cash flow
Cash from operating activities
(206,271)
(145,587)
(112,308)
CAPEX
(10,986)
(10,841)
Cash from investing activities
(394,552)
(10,986)
(10,841)
Cash from financing activities
589,554
(883)
223,610
FCF
(168,279)
(237,906)
(276,145)
Balance
Cash
588,023
239,566
382,436
Long term investments
Excess cash
587,517
239,481
382,126
Stockholders' equity
(1,128,386)
(907,546)
(709,069)
Invested Capital
1,853,366
1,248,296
1,158,015
ROIC
ROCE
EV
Common stock shares outstanding
255,161
173,942
94,993
Price
2.35
-63.51%
6.44
238.95%
1.90
-63.39%
Market cap
599,628
-46.47%
1,120,186
520.64%
180,487
-51.76%
EV
116,863
991,607
(153,437)
EBITDA
(131,987)
(195,028)
(297,495)
EV/EBITDA
0.52
Interest
9,294
45,067
8,905
Interest/NOPBT